ImmuPharma plc (IMM.L)

2,0550 -0,0200 (-0,96%) A partir del 10:10AM BST. Mercado abierto.

ImmuPharma plc

1 Bartholomew Close
London EC1A 7BL
United Kingdom
44 20 7206 2650
https://www.immupharma.co.uk

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 13

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Timothy Paul McCarthy XIV, FCCA, M.B.A., MBA	Chairman & CEO	106,5k	N/A	1956
Dr. Timothy Gary Franklin M.B.A., Ph.D.	COO & Director	92,5k	N/A	1964
Ms. Lisa Baderoon	Head of Investor Relations & Non Executive Director	48k	N/A	1966
Dr. Jean-Marie Geiger PharmD, MD	Head of Clinical Development	N/A	N/A	N/A
Dr. Laura Mauran-Ambrosino Ph.D.	Chief Scientific Officer of ImmuPharma Biotech	N/A	N/A	N/A
Ms. Lara E. Sucheston-Campbell	Head of Clinical & Medical Affairs	N/A	N/A	N/A
Dr. Sébastien R. Goudreau Ph.D.	CEO of ImmuPharma Biotec & Director	N/A	N/A	1981

Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en GBp.

Descripción

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.

Gobierno corporativo

El ISS Governance QualityScore de ImmuPharma plc, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.